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CC BY-NC-ND license (http://creativeAbstract Vision loss or impairment resulting from the degeneration of the retinal pigment
epithelium and photoreceptor death affects millions worldwide. Recent exciting results from
clinical studies of small numbers of patients treated with human embryonic stem cell-derived
retinal pigment epithelial cells may provide hope for affected individuals.
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by-nc-nd/4.0/).Vision loss or impairment as a result of the degeneration of
the retinal pigment epithelium and the subsequent photo-
receptor death affects millions of people worldwide. Two
major causes of this condition include dry age-related
macular generation and Stargardt’s macular dystrophy.1,2of Pathology and Laboratory
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these conditions. Recently, two groups of investigators re-
ported exciting results from clinical studies of a small
number of patients treated with human embryonic stem
cell-derived retinal pigment epithelial cells.3,4 Schwartz
et al reported their results from a study of nine patients
with atrophic age-related macular generation and nine with
Stargardt’s macular dystrophy in The Lancet.3 Although the
trial was performed to examine the safety of the cell-based
therapy, assessments of its efficacy were also performed.
The patients had been followed up for a median of 22
months. The visual acuity improved in 10 eyes, remained
the same in seven eyes and decreased in one eye. Thereand hosting by Elsevier B.V. This is an open access article under the
4.0/).
294 J. Hu et al.were no adverse effects related to the cell therapy iden-
tified, suggesting that it is safe.
In another study published in Stem Cell Reports, Song
et al reported their treatment of two patients with dry age-
related macular degeneration and two patients with Star-
gardt’s macular dystrophy. They also used embryonic stem
cell-derived retinal pigment epithelial cells.4 The patients
in that study had a different ethnic background (Asian
rather than Caucasian). Their findings were consistent with
the results obtained by Schwartz et al. The patients showed
improvement in their visual acuity, and there were no side
effects associated with the treatment.
These studies demonstrated the possibility that human
embryonic stem cell-derived cells may provide a new
source of therapeutics for retinal degeneration, although
the mechanism(s) underlying the visual improvement is still
unclear. Since Stargardt’s disease affects photoreceptor
cells as well as retinal pigment epithelial cells, it is possible
that the transplantation of both photoreceptor cells and
retinal pigment epithelial cells would have even better
efficacy. Since the cells used were not autologous, immu-
nosuppressive agents were used for the first 12e14 weeks
after the transplant. However, since the retinal space is
considered to be an immune-privileged environment,5 it is
unclear whether immunosuppression is necessary. On the
other hand, if the cells being transplanted are immuno-
genic, immunosuppression for 12e14 weeks may not be
sufficient to allow the cells to survive for 22 months. Animal
studies would be useful to resolve whether the retinal
space tolerates heterologous cells. Since the embryonic
stem cells can provide an unlimited supply of cells, these
studies can shed new light on using human embryonic stem
cells to develop cell-based therapies for retinal diseases,
and perhaps also for other diseases.Conflict of interest disclosure
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